MedPath

Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream

Phase 3
Completed
Conditions
Superficial Basal Cell Carcinoma
Interventions
Registration Number
NCT00189306
Lead Sponsor
Graceway Pharmaceuticals, LLC
Brief Summary

An open-label study to evaluate the safety and the ability of Imiquimod 5% cream, applied topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up.

Detailed Description

Evaluate the long-term sustained clearance rate, defined as the proportion of those subjects clinically clear of basal cell carcinoma (BCC) at the treated superficial BCC (sBCC) target tumor site at the 12-week posttreatment visit who remain clear during a 5 year follow-up period.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
169
Inclusion Criteria
  • Have at least 1 previously untreated superficial basal cell carcinoma tumor
  • Minimum tumor size 0.5 cm2 and maximum diameter of 2.0 cm
Exclusion Criteria
  • Evidence of clinically significant, unstable medical conditions
  • Cannot have recent use of topical steroids or retinoids in the treatment area.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
AldaraImiquimod 5% creamAldara (imiquimod) cream 5% applied 7 times per week for 6 weeks
Primary Outcome Measures
NameTimeMethod
Number of Participants With Sustained Clearance Rate of Superficial Basal Cell Carcinoma (sBCC)5 years

Number of participants clinically clear of superficial basal cell carcinoma at the treated target tumor site at the 12-week posttreatment visit (ie, initial clearance rate) who remain clear during a 5 year follow-up period.

Secondary Outcome Measures
NameTimeMethod
Number of Participants Cleared of Superficial Basal Cell Carcinoma at 12 Weeks12 week posttreatment visit

Number of participants cleared at 12 weeks(the number of subjects with no clinical evidence of superficial basal cell carcinoma at the target tumor site at the 12-week posttreatment visit)

Trial Locations

Locations (18)

Freemantle Dermatology

🇦🇺

Fremantle, Western Australia, Australia

158 South Terrace

🇦🇺

Perth, Western Australia, Australia

Skin Centre

🇦🇺

Benowa, Queensland, Australia

Queen Elizabeth Hospital

🇦🇺

Woodville, South Australia, Australia

105 Fulham Road

🇦🇺

Gulliver, Queensland, Australia

Colombo Mansions

🇳🇿

Christchurch, New Zealand

Birthcare Building

🇳🇿

Parnell, Auckland, New Zealand

Dermatology Practice

🇳🇿

Christchurch, New Zealand

Skin Institute Limited

🇳🇿

Takapuna, New Zealand

Austin & Repartriation Hospital

🇦🇺

Heidelburg, Victoria, Australia

Princess Alexandra Hospital

🇦🇺

Woolloongabba, Queensland, Australia

South East Dermatology Centre

🇦🇺

Carina Heights, Queensland, Australia

103A Mountain Road

🇳🇿

Epsom, Auckland, New Zealand

Medical Centre, Concord Hospital

🇦🇺

Concord, New South Wales, Australia

Prince of Wales Hospital

🇦🇺

Randwick, New South Wales, Australia

Western Hospital

🇦🇺

Footscray, Victoria, Australia

Subiaco Clinic

🇦🇺

Subiaco, Western Australia, Australia

Flinders Medical Center

🇦🇺

Bedford Park, South Australia, Australia

© Copyright 2025. All Rights Reserved by MedPath